

# Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas

Esteban Braggio<sup>1</sup>, Scott Van Wier<sup>1</sup>, Juhi Ojha<sup>1</sup>, Ellen McPhail<sup>2</sup>, Yan W. Asmann<sup>3</sup>, Jan Egan<sup>1</sup>, Jackline Ayres da Silva<sup>4</sup>, David Schiff<sup>5</sup>, M. Beatriz Lopes<sup>5</sup>, Paul A. Decker<sup>2</sup>, Riccardo Valdez<sup>1</sup>, Raoul Tibes<sup>1</sup>, Bruce Eckloff<sup>2</sup>, Thomas E. Witzig<sup>2</sup>, A. Keith Stewart<sup>1</sup>, Rafael Fonseca<sup>1</sup>, and Brian Patrick O'Neill<sup>2</sup>

## Abstract

**Purpose:** Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system. Whether there is a PCNSL-specific genomic signature and, if so, how it differs from systemic diffuse large B-cell lymphoma (DLBCL) is uncertain.

**Experimental Design:** We performed a comprehensive genomic study of tumor samples from 19 immunocompetent PCNSL patients. Testing comprised array-comparative genomic hybridization and whole exome sequencing.

**Results:** Biallelic inactivation of *TOX* and *PRKCD* was recurrently found in PCNSL but not in systemic DLBCL, suggesting a specific role in PCNSL pathogenesis. In addition, we found a high prevalence of *MYD88* mutations (79%) and *CDKN2A* biallelic

loss (60%). Several genes recurrently affected in PCNSL were common with systemic DLBCL, including loss of *TNFAIP3*, *PRDM1*, *GNA13*, *TMEM30A*, *TBL1XR1*, *B2M*, *CD58*, activating mutations of *CD79B*, *CARD11*, and translocations *IgH-BCL6*. Overall, B-cell receptor/Toll-like receptor/NF- $\kappa$ B pathways were altered in >90% of PCNSL, highlighting its value for targeted therapeutic approaches. Furthermore, integrated analysis showed enrichment of pathways associated with immune response, proliferation, apoptosis, and lymphocyte differentiation.

**Conclusions:** In summary, genome-wide analysis uncovered novel recurrent alterations, including *TOX* and *PRKCD*, helping to differentiate PCNSL from systemic DLBCL and related lymphomas. *Clin Cancer Res*; 21(17): 3986–94. ©2015 AACR.

## Introduction

Primary central nervous system lymphoma (PCNSL) is an aggressive variant of non-Hodgkin lymphoma confined to the central nervous system. Most PCNSL (90%) are part of the immune-privileged site-associated diffuse large B-cell lymphomas (IPDLBCL). IPDLBCL consist of late-germinal center or post-germinal center lymphoid cells that show very distinct characteristics that separate them from nodal DLBCLs. IPDLBCL are now recognized as a distinct entity in the World Health Organization lymphoma classification (1).

Unlike nodal DLBCL, only a limited number of genetic studies have been performed in PCNSL, partly due to the lack of available tissue specimens because most cases are diagnosed by stereotactic biopsy. In addition to the low amount of available tissue for genomic analysis, the source of biologic samples is often limited to formalin-fixed and paraffin-embedded (FFPE) specimens. In

recent years, an improved understanding of PCNSL biology has emerged, largely from the use of modern high-throughput molecular techniques in FFPE specimens (2–5).

Several recurrent chromosomal abnormalities and mutations have been identified, such as mutations in *PRDM1* (6) and *CARD11* (7), translocations of *IgH-BCL6* (8), deletions of 6p21, 6q, 8q12, 9p21, and gains of 7q, 11q and chromosome 12 (3, 4, 9, 10). Recently, the first whole exome sequencing (WES) study was reported on 4 PCNSL patients, showing recurrent mutations in *MYD88*, *PIM1*, and *TBL1XR1* (5). Gene expression profiling studies suggested the existence of three gene "signatures" associated with PCNSL that resemble the classification proposed in systemic DLBCL (11). However, unique molecular features have been found in PCNSL suggesting implication of the brain microenvironment in neoplastic proliferation and central nervous system tropism for tumoral B cells (12, 13).

Nevertheless, because of the paucity of genomic data, little is known of how PCNSL differs from systemic DLBCL with respect to its molecular features and pathogenesis. To determine if there is a specific central nervous system signature, we report a comprehensive genomic study in tumor samples from 19 PCNSL patients that combined array-based comparative genomic hybridization (aCGH), whole exome sequencing, targeted sequencing, and FISH. Using this combinatorial approach, we found a complex karyotype and uncovering novel recurrent alterations, including loss/deletion of *TOX* and *PRKCD*, helping to differentiate PCNSL from systemic DLBCL and related lymphomas.

<sup>1</sup>Mayo Clinic, Scottsdale, Arizona. <sup>2</sup>Mayo Clinic, Rochester, Minnesota. <sup>3</sup>Mayo Clinic, Jacksonville, Florida. <sup>4</sup>National Institute of Cancer, Brazil. <sup>5</sup>University of Virginia, Charlottesville, Virginia.

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

**Corresponding Author:** Esteban Braggio, Mayo Clinic, 13400 E Shea Blvd, MCCR Building, Room 3-029, Scottsdale, AZ 85259. Phone: 480-301-4617; Fax: 480-301-8387; E-mail: [braggio.esteban@mayo.edu](mailto:braggio.esteban@mayo.edu)

**doi:** 10.1158/1078-0432.CCR-14-2116

©2015 American Association for Cancer Research.

### Translational Relevance

Primary central nervous system lymphoma (PCNSL) is an aggressive brain cancer characterized by a perivascular accumulation of malignant cells with lymphoid characteristics. Without translatable knowledge of the mechanisms of PCNSL development and progression, treatment falls on conventional managements, such as radiotherapy and chemotherapy. These treatments are intense, and the quality of survival is often poor.

This study revealed a previously unappreciated genetic complexity in immunocompetent PCNSL. We identified a related genomic landscape between PCNSL and activated B cell diffuse large B-cell lymphoma (ABC-DLBCL) but confirmed the existence of a specific molecular signature in PCNSL, reinforcing the idea that PCNSL is a different entity. Furthermore, this comprehensive genomic study identified targetable pathways in the disease. The identification of mutations affecting the B-cell receptor, Toll-like receptor, and NF- $\kappa$ B signaling pathways in most of the PCNSL cases highlights the potential value of these pathways as treatment targets in PCNSL.

## Patients and Methods

### Tumor samples

Samples from 19 immunocompetent (HIV<sup>-</sup> and EBV<sup>-</sup>) PCNSL were retrieved from the Mayo Clinic Tumor Registry (IRB approval 08-001933) and the University of Virginia (IRB approval 14225). A review of clinical histories confirmed that each case was newly diagnosed, was confined to the central nervous system, had no occult disease by standard staging (14), and that each patient had no apparent immunodeficiency. Clinical annotations, including pathology, treatment, follow-up, and survival data of the cohort, are shown in Supplementary Table S1.

Sections (5  $\mu$ m) were cut from each FFPE block and placed on clean glass slides. Slides were stained with hematoxylin and eosin to confirm the presence of sufficient tumor-rich tissue (>75%) without significant hemorrhage, necrosis, or artifact. Confirmatory immunohistochemistry using antibodies directed against CD20 and CD3 was performed on the second and third slide of each patient set. All confirmed cases were then screened for Epstein–Barr virus utilizing *in situ* hybridization probes that recognize EBV-encoded RNA.

### Molecular tests

DNA was obtained either from frozen tissue or from FFPE tissues. In a subset of 3 samples with frozen tissue available, the amount of DNA recovered was not enough for performing molecular techniques, so a whole genome amplification step was added (see below). In 9 of 19 samples, we identified biopsies that included tumor-free tissue. These tissues were used to extract normal DNA for validation sequencing. The source of DNA and the molecular techniques performed in each sample are described in Supplementary Table S2.

### DNA isolation

DNA was obtained from frozen tissue in 7 cases using Gentra Puregene Core A kit (Qiagen) according to the manufacturer's recommendations. In the remaining 12 cases, FFPE samples were deparaffinized using 3 xylene washes for 5 minutes each. Xylene

was washed out with decreasing series of ethanol (100%, 95%, 70%, 50%, 30%, 0%) and finally washed 3 times in 1 mmol/L EDTA (pH 8.0) for 5 minutes each. The tissue was pelleted and washed 2 times with PBS (pH = 7.5). Samples were incubated overnight with 180 mL tissue lysis buffer ATL (Qiagen) and 20 mL proteinase K. DNA was obtained using the MicroDNA extraction Kit according to the manufacturer's recommendations (MicroDNA kit; Qiagen).

In three samples with insufficient DNA available, amplification of the whole genome was performed using the illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare) following the manufacturer's recommendations. DNA concentration was measured by fluorometric method (Qubit).

### aCGH

aCGH was performed in 18 cases (Supplementary Table S2) using the Human Genome 244A and the Sureprint G3 microarrays (Agilent Technologies). The digestion, labeling, and hybridization steps were done as previously described (4, 15, 16). Briefly, 1.2  $\mu$ g of tumor and reference DNA were independently fragmented with Bovine DNaseI (Ambion) for 12 minutes at room temperature. DNA samples from a pool of 9 female, lymphoblastoid cell lines from the Coriell repository were used as the normal reference in the hybridization experiments. Tumor and reference samples were labeled with Alexa 5 and Alexa 3 dyes, respectively. Labeled reactions were cleaned up and hybridized at 65°C for 40 hours. Microarrays were scanned in a DNA Microarray Scanner, and features were extracted with Feature Extraction software (Agilent).

Extracted data were analyzed using Nexus software (Biodiscovery). Copy-number abnormalities (CNA) were calculated using RANK segmentation algorithm, a modified version of the circular binary segmentation algorithm. For CNA detection, a significant threshold was set at  $2.4E-5$  with a minimum number of probes per segment set at 2 (244K array format), 3 (Sureprint G3 in fresh tumor samples), or 10 (Sureprint G3 in FFPE samples). To identify and eliminate the germline copy-number variations (CNV) from the study, we created a CNV database, including the copy-number (using platform SNP6.0) and sequencing studies available in The Centre for Applied Genomics data portal (TCAG) as well as our findings in 10 HapMap samples run by Sureprint G3 arrays (16). Microarray data are deposited in GEO dataset under accession GSE28952.

### Whole exome end-paired sequencing

Exome capture was done utilizing the solution-phase hybrid Sure Select 50 MB Capture Kit (Agilent Technologies). Next, 100 bp paired-end DNA libraries were prepared, and 4 samples were run per lane on the HiSeq2000 sequencer. An automated workflow for exome-seq data analysis was developed, which includes read quality control, read alignment, and mutation detection. Paired-end reads were aligned to hg19 using Novoalign (Novocraft Technologies). Quality of sequencing chemistry was evaluated using FastQC. After alignment, PCR duplication rates and percent reads mapped on target were used to assess the quality of the sample preparations. Realignment and recalibration steps were done based on the Best Practice Variant Detection v3 recommendations implemented in The Genome Analysis Toolkit (GATK; ref. 17). Duplicate marking was used to flag those reads in the alignment file—without removing them—and afterwards the SNV callers do not consider reads with the duplicate flag for the

analysis. Germline variant calling (both single nucleotide and small insertions and deletions) was also called through GATK. Somatic single-nucleotide variations (SNV) were genotyped using SomaticSniper (18), whereas insertions and deletions were called by GATK Somatic Indel Detector. Each variant in coding regions was functionally annotated by snpEFF and PolyPhen-2 (19) to predict biologic effects. The variants were annotated using our TREAT workflow (20) whether or not the gene is associated with disease or phenotypes, and any associated pathways. We removed variants found in the 1000 genomes project, the HapMap sequencing project, and the BGI—Danish Sequencing Project. In addition, we removed variants present in the dbSNP dataset unless these mutations were also present in the COSMIC database. Variants of significant interest were visually inspected using Integrative Genomics Viewer (IGV) (21).

### Validation sequencing

**Targeted sequencing.** All the coding regions of *MYD88* were sequenced using semiconductor technology (IonTorrent PGM; Life Technologies) following the manufacturer's recommendations (22). All the coding regions were amplified in 150 bp amplicons using customized oligos (Ion Ampliseq designer; Life Technologies) and multiplex PCR with 10 ng of input DNA per reaction. DNA libraries preparation and enrichment were done using the IonOneTouch and IonOneTouch ES automated systems, respectively. Samples were sequenced using the 316 chip, with an average of 2,005× depth of coverage per nucleotide. Data were analyzed using IonReporter software (Life Technologies).

**Sanger sequencing.** All mutations identified by WES in *CARD11*, *CD79B*, *PRKCD*, and *TNFAIP3* were validated using PCR amplification followed by Sanger sequencing. In each case, tumor and normal counterpart samples were sequenced to confirm the somatic origin of the mutations. List of primers used for PCR and sequencing is listed in Supplementary Table S3.

### Interphase FISH

Interphase FISH was performed on sections of FFPE ( $N = 9$ ) or frozen tumor samples ( $N = 2$ ) as described previously (23). The 11 cases were screened for *IGH-BCL6* translocations. For *IGH-BCL6*, we used a two-color break-apart probe for *BCL6* (BAP; Abbott Molecular) and a homebrew two-color dual-fusion *IGH-BCL6* probe composed of a SpectrumGreen-labeled probe for 14q32 and a SpectrumOrange-labeled probe for 3q27.3 (BACS RP11-88P6, RP11-211G3, and CTD2522K3). For *PRKCD* and *TOX*, homebrew probes were used: *PRKCD*: G248P8797G3/WI2-1696N05; *TOX*: G248P80762C4/WI2-1217E08 (Genome Reference Consortium). Control probes were used in both cases: *CEP3* (SpectrumOrange) with *PRKCD* (SpectrumGreen) and *LSI C-MYC* (SpectrumOrange) with *TOX* (SpectrumGreen). Three patients were screened for each, *PRKCD* and *TOX*. In each sample, at least 50 tumor cells were scored. Samples were scored as positive when at least 20 cells with a recognized abnormal signal pattern were present (24). The list of cases analyzed and the respective results for each region are shown in Supplementary Table S4.

### Gene expression analysis

Gene expression levels of *PRKCD* and *TOX* were analyzed using publicly available datasets. Expression level across different tumor

cell lines was obtained from the Broad-Novartis Cancer Cell Line Encyclopedia.

### Functional gene set enrichment

Enrichment of functional gene classes within frequently abnormal genes was performed using the DAVID Functional Annotation tool.

### Statistical analysis

Overall survival (OS) was estimated using the Kaplan–Meier method. Differences between survival curves were estimated by the log-rank test. Results were considered significant when  $P < 0.05$ .

## Results

### Analysis of chromosomal abnormalities shows a complex karyotype in PCNSL


To identify genetic abnormalities in PCNSL, we screened 18 patient samples by aCGH (Fig. 1). PCNSL cases showed a complex genome with a median of 21 CNA per patient (range, 10–47). Overall, 16 chromosomal abnormalities were found in >25% of cases (10 deletions and 6 gains). The most common abnormality was the deletion of 9p21.3 (*CDKN2A* and *CDKN2B*), which was found in 83% of cases. Multiple abnormalities were commonly found in chromosome 6. Deletion of 6p21 (HLA genes) was identified in 9 of 18 cases (50%), losses of 6q21 (*PRDM1*) and 6q23 (*TNFAIP3*) in 10 cases each (55%), and deletion of 6q14.1 (*TMEM30A*) in 8 cases (44%). Of the remaining lesions found in >25% of cases, 6 encompassed single or few genes, including losses of 3p21 (*PRKCD*), 3q26.32 (*TBL1XR1*), 8q12 (*TOX*), 12q24.31 (*BCL7A*, *SETD1*, and 9 other genes) and gains of 3p14 (*FOXP1*) and 3q27 (*BCL6*; Fig. 1). *BCL6* and *FOXP1* were characterized by breakpoints inside the gene or near 5' of the gene, suggesting their involvement in unbalanced chromosomal translocations. Other recurrent abnormalities were gains of 7q21-q31 (39%), 11q (28%), 12q (50%), and 19q13 (33%) and loss of 10p15.3-p14 (33%). Gain of 12q was mutually exclusive with deletion 10p15.3-p14 and gains of 3p14 (*FOXP1*) and 11q, which were found alone or in combination in all 9 cases without gain of 12q ( $P = 0.0004$ ; Supplementary Fig. S1). Furthermore, losses of 3p21.31 (*PRKCD*) and 6q23 (*TNFAIP3*) were rare events in cases with 12q. The complete list of CNA is listed in Supplementary Table S5.

Next, we focused on the analysis of homozygous deletions (HD) and high-copy gain, which are likely to harbor tumor-suppressor genes and oncogenes, respectively. Overall, 13 HD and 4 high-copy level gain were found; 55% of cases analyzed show HD of *CDKN2A*, whereas another 21% showed monoallelic deletion of the gene. Recurrent HD were also found in HLA genes in 22% (4/18), *PRDM1*, *TMEM30A*, *TOX*, and *CD58* (in 2 cases each; 11%). Another 34 genes, including *B2M*, *ETV6*, *TNFAIP3*, and *TNFRSF10A*, were found deleted in individual cases (Table 1). Conversely, high-level amplifications were rare in PCNSL. Overall, only four regions were identified having 2 or more extra copies: 1p31.1-p22.2 (*BCL10* and other 32 genes), 7p22.3-p22.2 (*CARD11* and other 36 genes), 12q14.1-q21.33, and 18q21.2 (*TCF4*), in one sample each.

Finally, *BCL6* translocations were identified in 2 of 11 PCNSL cases analyzed. Both cases showed *IGH-BCL6* fusion (Supplementary Fig. S2A and Supplementary Table S4).

**Figure 1.**

Overview of copy-number abnormalities identified in the cohort of PCNSL analyzed. Chromosomes 1 to Y are represented from left to right. Dark gray blocks represent chromosome gains, whereas light gray blocks represent chromosome losses. The amplitude in each abnormal region represents the incidence of each copy-number abnormality in the studied cohort. Genes found in recurrent minimal aberrant regions (>25%) are indicated.



**Amplified genomic DNA and DNA extracted from FFPE blocks were suitable for WES**

We analyzed 10 PCNSL by WES with an average of 65.6 million mapped reads in capture regions. After duplication marking and removal, we obtained a median of 80% of the exome covered by 30x depth or more. In 3 cases, DNA was extracted from FFPE tissue. In the remaining 7 cases, DNA was obtained from frozen tissue. In 3 of these 7 cases, there was not enough input genomic DNA, and a whole genome amplification step was added before proceeding (Supplementary Table S2). Sequencing data generated from amplified DNA and from FFPE samples showed a lower coverage than the data generated from high molecular weight genomic DNA, but still showed satisfactory quality control measurements and average fold coverage for the analysis (Supple-

mentary Table S6). After data filtering, we found a mean non-synonymous mutation rate of 3.3 mutations per Mb (range, 0.8 to 6.1 mutations per Mb). The complete list of mutated genes is shown in Supplementary Table S7.

**Integrated mutation and copy-number data identified PCNSL-specific abnormalities**


By analyzing mutation data (Fig. 2) and integrating mutation and copy-number data (Fig. 3), we identified a group of genes recurrently activated and/or biallelically mutated in PCNSL that has not been previously identified in nodal DLBCL, including *PRKCD* and *TOX*. Protein kinase C delta (*PRKCD*) emerged as a potentially relevant gene in PCNSL. We identified mutations affecting splice donor sites in 2 of 10 cases analyzed by WES.

**Table 1.** Chromosomal regions implicated either in homozygous deletions (HD) or >2 extra copies (amplification). Genomics coordinates represent the minimal affected regions calculated using aCGH data

| Chr | Cytoband    | Start_bp  | End_bp    | Size (Mb) | Change        | Number of cases (%) | Genes                                                                            |
|-----|-------------|-----------|-----------|-----------|---------------|---------------------|----------------------------------------------------------------------------------|
| 1   | p35.2       | 30438023  | 31187531  | 0.75      | HD            | 1 (5)               | <i>MATN1, LAPTMS, SDC3, PUM1, SNORD103A</i>                                      |
| 1   | p13.1       | 116859897 | 117098412 | 0.24      | HD            | 2 (11)              | <i>CD58, IGSF3</i>                                                               |
| 4   | q34.3       | 178684938 | 181419558 | 2.73      | HD            | 1 (5)               | <i>LINC01098</i>                                                                 |
| 6   | p21.32      | 32716055  | 32728687  | 0.01      | HD            | 4 (22)              | <i>HLA</i>                                                                       |
| 6   | q14.1       | 76013320  | 76023847  | 0.01      | HD            | 2 (11)              | <i>TMEM30A</i>                                                                   |
| 6   | q21         | 106645690 | 106658114 | 0.01      | HD            | 2 (11)              | <i>PRDM1</i>                                                                     |
| 6   | q21         | 108337759 | 108342883 | 0.01      | HD            | 1 (5)               | <i>SEC63</i>                                                                     |
| 6   | q26         | 161563675 | 161586174 | 0.02      | HD            | 1 (5)               | <i>AGPAT4</i>                                                                    |
| 7   | p15.1       | 30094975  | 30096933  | 0.002     | HD            | 1 (5)               | <i>PLEKHA8</i>                                                                   |
| 8   | p21.3       | 22934625  | 23145415  | 0.21      | HD            | 1 (5)               | <i>TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF10A</i>                                |
| 8   | q12.1       | 59996016  | 60127073  | 0.13      | HD            | 2 (11)              | <i>TOX</i>                                                                       |
| 9   | p21.3       | 21961516  | 21988776  | 0.08      | HD            | 10 (56)             | <i>CDKN2A, CDKN2B</i>                                                            |
| 12  | p13.2       | 11787795  | 11985797  | 0.2       | HD            | 1 (5)               | <i>ETV6</i>                                                                      |
| 15  | q15.3-q21.1 | 42663648  | 43310674  | 0.65      | HD            | 1 (5)               | <i>SPG11, PATL2, B2M, TRIM69, c15orf43, SORD, DUOX2, DOUXA1, DOUX1, SHF</i>      |
| 16  | q12.2       | 51781157  | 51921599  | 0.14      | HD            | 1 (5)               | <i>CHD9</i>                                                                      |
| 17  | q24.1       | 60452046  | 60482005  | 0.03      | HD            | 1 (5)               | <i>GNAI3</i>                                                                     |
| 19  | q13.12      | 42005151  | 42137239  | 0.13      | HD            | 1 (5)               | <i>ZNF790, ZNF345, ZNF829, ZNF568</i>                                            |
| X   | q27.1       | 138466967 | 138747086 | 0.28      | HD            | 1 (5)               | <i>F9, MCF2, APT1IC</i>                                                          |
| X   | q28         | 150511563 | 151661046 | 1.15      | HD            | 1 (5)               | <i>PASD1, PRRG3, FATE1, CNGA2, MAGEA4, GABRE, MAGEA5, MAGEA10, GABRA3, GABRQ</i> |
| 5   | q22.1       | 110445097 | 110474082 | 0.03      | Amplification | 1 (5)               | <i>WDR36</i>                                                                     |
| 7   | p12.2       | 50114207  | 50502559  | 0.39      | Amplification | 1 (5)               | <i>c7orf72, IKZF1, FIGNL1, DDC</i>                                               |
| 18  | q21.2       | 51053466  | 51141361  | 0.09      | Amplification | 1 (5)               | <i>TCF4</i>                                                                      |
| 1   | p31.1-p22.2 | 82724188  | 88291462  | 5.57      | Amplification | 1 (5)               | <i>BCL10 (37)</i>                                                                |
| 7   | p22.3       | 178408    | 4945057   | 4.77      | Amplification | 1 (5)               | <i>CARD11 (33)</i>                                                               |
| 19  | p13.3       | 1567089   | 1584543   | 0.02      | Amplification | 1 (5)               | <i>TCF3</i>                                                                      |
| 7   | p11.2       | 55464898  | 55602703  | 0.14      | Amplification | 1 (5)               | <i>LANCL2, VOPPI</i>                                                             |
| 16  | q24.1       | 84486886  | 84587286  | 0.1       | Amplification | 1 (5)               | <i>IRF8</i>                                                                      |

Note: In regions larger than 1 Mb, only the most relevant genes were listed (numbers in parentheses indicate the total number of genes included in those regions).

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/21/17/3989/2025093/3989.pdf by guest on 08 October 2024



**Figure 2.** Recurrent mutations in PCNSL. The columns of the heatmap represent individual patients. Type of mutation found is color-coded. In cases with multiple mutations in the same gene, a combination of colors (more than one type of mutations) or numbers indicating the number of mutations found (more than one mutation of the same type) was used. Right: histogram showing the incidence of mutations found in each gene.

One of these cases had an additional missense mutation (p. W608S). Sanger sequencing confirmed all mutations. Next, the somatic origin of the mutations was confirmed by the lack of them in normal tissue sequenced from both cases. Furthermore, both cases also showed monoallelic deletion of *PRKCD*, thus confirming the biallelic loss of the gene (Fig. 4). In addition, we identified focal monoallelic deletions (<1 Mb) involving *PRKCD* in another 3 of 18 cases analyzed by aCGH (Fig. 1B and Supplementary Fig. S2B). DNA was not available for sequencing these 3 cases. Mutations in *PRKCD* have not been found in nodal DLBCL. Furthermore, COSMIC dataset (Sanger Institute) only shows *PRKCD* mutations in one sample (p.A163T; acute lymphoblastic leukemia) of 1,058 hematological malignancies analyzed (0.01%), thus suggesting that *PRKCD* impairment is specific to PCNSL. Using public datasets, we analyzed the expression level of *PRKCD* across cell lines established from different types of cancer. Using the Broad-Novartis dataset, we found that DLBCL shows the highest expression of *PRKCD* across all entities.


Another interesting finding was the recurrent abnormalities affecting thymocyte selection-associated high-mobility group box (*TOX*) gene seen only in PCNSL. Thus, 11% of PCNSL showed homozygous deletion of *TOX* and another 17% of cases showed focal monoallelic deletions in the gene (Fig. 5 and Supplementary Fig. S2C). In comparison, no homozygous deletions affecting

*TOX* were identified across 754 cell lines analyzed, including 127 lines originated from hematopoietic and lymphoid tissues (Source: Cancer Genome Project dataset, Sanger Institute).

On the other hand, we found recurrent mutations in several genes that are linked to DLBCL pathogenesis, principally the high prevalence of *MYD88*-activating mutations, found mutated in 70% of cases by WES (Fig. 2). We additionally screened another 4 PCNSL cases for *MYD88* mutations by targeted sequencing. Overall, mutations were found in 11 of 14 cases analyzed (79%). The mutations were found in the residue L265P, with the exception of two mutations, affecting the residue 217 (V217F) and the residue 232 (M232T), respectively. The prevalence of *MYD88* mutations found is nearly 2-fold higher than what has been reported in nodal activated B cell (ABC)-DLBCL.

Other affected genes shared with nodal DLBCL were mutations on *CD79B* (40%), *PIM1*, *BTG2*, *CARD11* (30% each), *GNA13*, *TNFAIP3* (20% each), and *BRAF* (10%). Three of 4 cases with *CD79B* mutations also have mutations affecting *MYD88* (Fig. 2). All mutations found in *CD79B*, *CARD11*, and *TNFAIP3* as well as its somatic origin were confirmed using Sanger sequencing.

Genomic data integration highlighted the high frequency of genetic lesions affecting a variety of signaling pathways that share their ability to induce the NF-κB transcription complex, including the B-cell receptor (BCR), CD40, and Toll-like receptor (TLR)



**Figure 3.** Integration of copy-number and sequencing data shows a set of recurrent abnormalities. List of genes that were affected with activating mutations/translocations/high-copy gain (top) or biallelic loss (bottom).

pathways. Overall, we found components of these pathways to be altered in 93% of PCNSL. Furthermore, our data showed the recurrent impairment of networks associated with proliferation,

immune response, regulation of apoptosis, and lymphocyte differentiation and activation.


**Abnormalities in 6q21 are associated with worse outcome**

To determine if there was an association between the identified recurrent abnormalities and survival, we compared the OS in patients with and without abnormalities found in >20% of cases. Deletion of 6q21 (*PRDM1*) was associated with shorter OS in univariate analysis ( $P = 0.001$ ; Supplementary Fig. S3). However, this observation needs to be considered with caution, especially considering the small size and heterogeneous treatment received by the cohort under analysis.


**Discussion**

Unlike systemic DLBCLs, only a small number of genetic studies have been performed in PCNSL (2–5, 7, 10, 11, 13), mainly because of the limited amount and source of material for study. Most PCNSL biopsies are obtained by stereotactic surgery and then placed in FFPE blocks. Therefore, the use of samples in systematic genomic studies has been challenging because the yield of DNA obtained from this source is low and the quality is poor. We have previously shown that DNA samples obtained from FFPE tissues can be used for array-based genomic analysis in PCNSL (4). FFPE specimens are valuable material for PCNSL research, especially in retrospective studies with long follow-up data. Thus, the data provided in our study encouraged the future interrogation of large archival PCNSL tissues by WES.

PCNSL are recognized as a distinct entity by the World Health Organization (WHO) classification, showing characteristics that separate them from nodal DLBCLs (1). However, only a few studies have been focused on better understanding the genomic landscape of PCNSL and the comparison with the better-defined nodal DLBCL. For example, recent studies have shown that



**Figure 4.** *PRKCD* is recurrently inactivated in PCNSL. Concomitant *PRKCD* monoallelic deletions (blue bars, top figure) and mutations affecting both alleles (bottom figures) were recurrently found in PCNSL.



**Figure 5.** Homozygous (top 2 samples) and focal heterozygous deletions (bottom 3 samples) affecting *TOX* were recurrently found in PCNSL.

PCNSL shares several abnormalities with DLBCL, including translocations of IgH-BCL6, deletions of 9p21, and mutations in *MYD88* and *CARD11* (3–5, 7, 25–27). Montesinos-Rongen and colleagues performed a comparative gene expression analysis and proposed that PCNSL are a post-germinal center disease associated with the ABC-DLBCL type in origin (11). Other gene expression studies have found similarities between entities, but also showed pathways unique to PCNSL (2, 9, 10, 13). In this study, we aimed to perform a comprehensive genomic study in PCNSL to better elucidate the genomic landscape of the disease.

By integrating copy-number and mutation data, we found a highly complex karyotype with a subset of PCNSL-specific alterations, thus reinforcing the idea that IP-DLBCLs are a pathogenetically distinct group. One of the novel and interesting findings is the recurrent abnormalities identified in *PRKCD*; no other hematological malignancy shows recurrent abnormalities in this gene. *PRKCD*, a proapoptotic protein kinase, has been implicated in a wide variety of cellular processes, such as growth, differentiation, secretion, apoptosis, and tumor development (28–31). In addition, numerous studies in humans and mice have shown that loss of *PRKCD* is associated with defective B-cell apoptosis, B-cell hyperproliferation, and autoimmune disorders (32–35). Furthermore, the decreased expression of *PRKCD* via the negative regulation of MiR-181a confers resistance of cervical cancer to radiation therapy, inhibiting irradiation-induced apoptosis and decreasing G<sub>2</sub>–M block (36). The study by Ke and colleagues shows that MiR-181a contributes to radioresistance by targeting *PRKCD*, leading to inhibition of radiation-induced apoptosis (36). Radio-insensitive cervical cancer specimens had higher expression of MiR-181a, compared with radiosensitive cases. MiR-181a negatively regulates the expression of *PRKCD* via targeting its 3′-untranslated region. These results suggest that lack of *PRKCD* expression might be a biomarker for insensitivity of radiation treatment in cervical cancer, but perhaps these results can be extrapolated to other cancers.

Another relevant finding was the identification of recurrent biallelic alterations of *TOX*. This gene plays a key role in T-cell development (37, 38). The absence of *TOX* prevents CD4 lineage T-cell development, including natural killer T (NKT) and T regulatory (Treg) CD4 T-cell sublineages, but has only modest effects on CD8 T-cell development (39). Furthermore, *TOX*-deficient mice (TKO) lacked lymph nodes and had a significant decrease in the frequency and size of Peyer's patches (40). A recent study

provides data that support an important role of *TOX* expression in B-cell biology (41). *TOX* was identified as one of the top differentially expressed genes between memory B cells (IgG<sup>+</sup> CD27<sup>+</sup>) and marginal zone B cells (IgD<sup>+</sup> CD27<sup>+</sup>). More specifically, it was shown that *TOX* is >10× underexpressed in MZB compared with memory B cells. As yet there is no known role of *TOX* in PCNSL, the recurrent alterations of this gene lead to speculate that *TOX* may contribute to its pathogenesis. Interestingly, our analysis suggested that loss of *TOX* is associated with shorter OS. Further studies, in larger cohorts of PCNSL with robust age, performance status, comorbidity, and treatment data, will be required to confirm this finding.

Moreover, we identified that almost all PCNSL cases (~90%) harbor mutations leading to activation of the NF-κB signaling pathway, such as activating mutations of *MYD88*, *CARD11*, and *CD79* and deletions of *TNFAIP3* and *TBL1XR1*. These data suggest that the activation of NF-κB signaling pathway is a key driver of lymphomagenesis in PCNSL, an immune-privileged site. Inside the pathway, the high prevalence of *MYD88*-activating mutations is remarkable. *MYD88* has become a central gene of B-cell pathogenesis, with mutations found in ABC-DLBCL, being ubiquitous in Waldenström's Macroglobulinemia and to a lesser extent in marginal zone lymphoma and chronic lymphocytic leukemia (42–48). Furthermore, three recent studies have been performed in PCNSL showing numbers ranging from 38% to 75% of cases with *MYD88* activating mutations (5, 25, 49).

In summary, we identified a related genomic landscape between PCNSL and ABC-DLBCL but reinforcing the existence of a specific molecular signature in PCNSL characterized by recurrent alterations in *PRKCD* and *TOX*. Furthermore, this comprehensive genomic study identified targetable pathways in the disease. PCNSL is an aggressive malignancy, and better and more specific treatments are needed. The identification of mutations affecting the BCR, TLR, and NF-κB signaling pathways in most of the PCNSL cases highlights the potential value of these pathways to be targeted in PCNSL.

#### Disclosure of Potential Conflicts of Interest

R. Fonseca reports receiving commercial research grants to Celgene; other research grants from Amgen, Cylene, and Onyx; speakers bureau honoraria from Amgen, Celgene, Cylene, and Onyx; and is a consultant/advisory board member for Amgen, Celgene, Cylene, and Onyx. No potential conflicts of interest were disclosed by the other authors.

## Authors' Contributions

**Conception and design:** E. Braggio, P.A. Decker, R. Valdez, A. Keith Stewart, R. Fonseca, B.P. O'Neill

**Development of methodology:** E. Braggio, Y.W. Asmann, J.A. da Silva, R. Fonseca

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** E. Braggio, J. Ojha, E. McPhail, D. Schiff, M.B. Lopes, R. Valdez, R. Tibes, B. Eckloff, T.E. Witzig, B.P. O'Neill

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** E. Braggio, J. Ojha, E. McPhail, Y.W. Asmann, M.B. Lopes, P.A. Decker, R. Valdez, R. Fonseca, B.P. O'Neill

**Writing, review, and/or revision of the manuscript:** E. Braggio, E. McPhail, Y.W. Asmann, J. Egan, D. Schiff, M.B. Lopes, P.A. Decker, R. Valdez, R. Tibes, T.E. Witzig, A. Keith Stewart, R. Fonseca, B.P. O'Neill

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** E. Braggio, S. Van Wier, J. Egan, R. Tibes, T.E. Witzig, R. Fonseca, B.P. O'Neill

**Study supervision:** E. Braggio, R. Valdez

**Other (clinical translational input for the design of trial):** R. Tibes

## References

- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
- Richter J, Ammerpohl O, Martin-Subero JI, Montesinos-Rongen M, Bibikova M, Wickham-Garcia E, et al. Array-based DNA methylation profiling of primary lymphomas of the central nervous system. *BMC Cancer* 2009;9:455.
- Schwindt H, Vater I, Kreuz M, Montesinos-Rongen M, Brunn A, Richter J, et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. *Leukemia* 2009;23:1875–84.
- Braggio E, McPhail ER, Macon W, Lopes MB, Schiff D, Law M, et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. *Clin Cancer Res* 2011;17:4245–53.
- Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurence A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. *Clin Cancer Res* 2012;18:5203–11.
- Courts C, Montesinos-Rongen M, Brunn A, Bug S, Siemer D, Hans V, et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. *J Neuropathol Exp Neurol* 2008;67:720–7.
- Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. *Acta Neuropathol* 2010;120:529–35.
- Montesinos-Rongen M, Zuhlke-Jenisch R, Gesk S, Martin-Subero JI, Schaller C, Van Roost D, et al. Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. *J Neuropathol Exp Neurol* 2002;61:926–33.
- Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. *J Pathol* 2008;216:209–17.
- Sung CO, Kim SC, Karnan S, Karube K, Shin HJ, Nam DH, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. *Blood* 2011;117:1291–300.
- Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim WK, Klapper W, et al. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. *Leukemia* 2008;22:400–5.
- Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al. Gene expression and angiotropism in primary CNS lymphoma. *Blood* 2006;107:3716–23.
- Tun HW, Personett D, Baskerville KA, Menke DM, Jaecle KA, Kreinest P, et al. Pathway analysis of primary central nervous system lymphoma. *Blood* 2008;111:3200–10.
- Ferreri AJ. How I treat primary CNS lymphoma. *Blood* 2011;118:510–22.
- Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in

## Acknowledgments

E. Braggio is a recipient of the Marriott Specialized Workforce Development Awards in Individualized Medicine, The Henry Predolin Foundation Career Development Award, and the George Haub Family Career Development Award Fund in Cancer Research.

## Grant Support

This work was supported by the Mayo Clinic SPOR in Brain Cancer (P50 CA108961; Principal Investigator: B.P. O'Neill), the Iowa/Mayo Lymphoma SPOR (P50 CA97274; Principal Investigators: George Weiner and Thomas Witzig), the George Haub Family Career Development Award Fund in Cancer Research, Steve's Run grant and the Henry Predolin Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 18, 2014; revised December 10, 2014; accepted May 3, 2015; published OnlineFirst May 19, 2015.

- two negative regulators of nuclear factor-kappaB signaling pathways in Waldenström's macroglobulinemia. *Cancer Res* 2009;69:3579–88.
- Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, et al. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. *Cancer Genet Cytogenet* 2011;203:161–8.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–303.
- Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. *Bioinformatics* 2012;28:311–7.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods* 2010;7:248–9.
- Pek JW, Kai T. DEAD-box RNA helicase Belle/DDX3 and the RNA interference pathway promote mitotic chromosome segregation. *Proc Natl Acad Sci U S A* 2011;108:12007–12.
- Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol* 2011;29:24–6.
- Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. *Nature* 2011;475:348–52.
- Cataldo KA, Jalal SM, Law ME, Ansell SM, Inwards DJ, Fine M, et al. Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. *Am J Surg Pathol* 1999;23:1386–92.
- Remstein ED, Dogan A, Einerson RR, Paternoster SF, Fink SR, Law M, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. *Am J Surg Pathol* 2006;30:1546–53.
- Montesinos-Rongen M, Godlewska E, Brunn A, Wiestler OD, Siebert R, Deckert M. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. *Acta Neuropathol* 2011;122:791–2.
- Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. *J Clin Oncol* 2008;26:4814–9.
- Montesinos-Rongen M, Schafer E, Siebert R, Deckert M. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. *Acta Neuropathol* 2012;124:905–6.
- Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaehtle C, Kazanietz MG, et al. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. *J Biol Chem* 1993;268:6090–6.



29. Pessino A, Passalacqua M, Sparatore B, Patrone M, Melloni E, Pontremoli S. Antisense oligodeoxynucleotide inhibition of delta protein kinase C expression accelerates induced differentiation of murine erythroleukemia cells. *Biochem J* 1995;312 (Pt 2):549–54.
30. Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, Emoto Y, et al. Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. *J Exp Med* 1996;184:2399–404.
31. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S, Foster DA. Tumor promotion by depleting cells of protein kinase C delta. *Mol Cell Biol* 1997; 17:3418–28.
32. Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. *Blood* 2013;121: 3117–25.
33. Belot A, Kasher PR, Trotter EW, Foray AP, Debaud AL, Rice GI, et al. Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. *Arthritis Rheum* 2013;65:2161–71.
34. Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. *Nature* 2002;416:865–9.
35. Limnander A, Depeille P, Freedman TS, Liou J, Leitges M, Kurosaki T, et al. STIM1, PKC-delta and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. *Nat Immunol* 2011;12:425–33.
36. Ke G, Liang L, Yang JM, Huang X, Han D, Huang S, et al. MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the proapoptotic PRKCD gene. *Oncogene* 2013;32:3019–27.
37. Aliahmad P, O'Flaherty E, Han P, Goularte OD, Wilkinson B, Satake M, et al. TOX provides a link between calcineurin activation and CD8 lineage commitment. *J Exp Med* 2004;199:1089–99.
38. Wilkinson B, Chen JY, Han P, Rufner KM, Goularte OD, Kaye J. TOX: an HMG box protein implicated in the regulation of thymocyte selection. *Nat Immunol* 2002;3:272–80.
39. Aliahmad P, Kaye J. Development of all CD4 T lineages requires nuclear factor TOX. *J Exp Med* 2008;205:245–56.
40. Aliahmad P, de la Torre B, Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. *Nat Immunol* 2010;11:945–52.
41. Descatoire M, Weller S, Irtan S, Sarnacki S, Feuillard J, Storck S, et al. Identification of a human splenic marginal zone B cell precursor with NOTCH2-dependent differentiation properties. *J Exp Med* 2014;211: 987–1000.
42. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. *Nature* 2011; 470:115–9.
43. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* 2011;475:101–5.
44. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat Genet* 2012;44:47–52.
45. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. *N Engl J Med* 2011;365:2497–506.
46. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. *N Engl J Med* 2012;367: 826–33.
47. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. *Blood* 2013;121:2522–8.
48. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. *Blood* 2013;121:2051–8.
49. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. *Blood Cancer J* 2013;3:e139.